Yue X, Hincapie AL, Li Y, Guo JJ, et al. Safety and cost-effectiveness of ponatinib versus other tyrosine kinase inhibitors as second-line therapy in patients with chronic myeloid leukemia in the United States. Leuk Lymphoma 2021 Nov 15:1-9. doi: 10.1080/10428194.2021.2002320.
PMID: 34775888